Comprehensive analysis of zolbetuximab’s regular purchase channels at home and abroad

Zolbetuximab (Zolbetuximab-clzb), as an innovative targeted therapy drug, has been officially launched in China. Although it has only entered the domestic market for a short period of time, the specific selling price is not yet completely clear, and it is not included in the medical insurance catalog. Therefore, patients need to consult with regular medical institutions or designated pharmacies when purchasing to obtain the latest prices and purchasing policies. Due to the lack of medical insurance support, the cost of medication for patients is relatively high, and financial planning needs to be done in advance.

In overseas markets, zotuximab has been approved for use in many countries and regions, especially in Europe and Japan, where it has the supply of original drugs. The specifications of the European and Japanese versions of zotuximab are mostly 100mg per box, and the price is usually around 7,000 yuan. The price will fluctuate due to exchange rate changes and market factors. Overseas drug channels are relatively mature, but patients need to purchase them through legal medical channels or officially authorized pharmacies to avoid the risk of illegal or counterfeit drugs.

There is currently no generic version of zotuximab available globally, which means patients can only rely on the supply of the original drug. Since the drug is a new biological agent with complex production processes and a long patent protection period, it will take time to develop and market generic drugs. If patients purchase generic drugs through informal channels, there is a risk that the quality of the drugs cannot be guaranteed, which may affect the treatment effect or even harm their health in severe cases.

In summary, when patients purchase zotuximab at home and abroad, they should give priority to regular medical institutions and authorized pharmacies to ensure the legality, quality and safety of the drug. With the passage of time and the development of the market, the price and purchase channels of zotuximab are expected to gradually improve and be transparent in the future, bringing convenience and good news to more patients.

Reference materials:https://www.astellas.com/en/news/29401